BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $262,593 | -20.9% | 3,857,666 | -5.2% | 0.04% | -17.4% |
| Q2 2023 | $332,025 | +781.5% | 4,067,429 | +701.2% | 0.05% | +666.7% |
| Q1 2023 | $37,664 | -57.5% | 507,648 | -52.5% | 0.01% | -57.1% |
| Q4 2022 | $88,624 | -99.9% | 1,069,311 | +268.6% | 0.01% | +7.7% |
| Q3 2022 | $82,379,000 | -5.5% | 290,065 | +15.3% | 0.01% | +18.2% |
| Q2 2022 | $87,181,000 | -22.3% | 251,502 | -3.0% | 0.01% | 0.0% |
| Q1 2022 | $112,264,000 | -19.6% | 259,246 | -3.9% | 0.01% | -15.4% |
| Q4 2021 | $139,595,000 | +20.8% | 269,832 | +13.2% | 0.01% | +18.2% |
| Q3 2021 | $115,554,000 | +63.1% | 238,468 | +51.6% | 0.01% | +57.1% |
| Q2 2021 | $70,831,000 | +9.0% | 157,312 | -7.6% | 0.01% | 0.0% |
| Q1 2021 | $65,007,000 | +14.5% | 170,207 | -4.8% | 0.01% | +16.7% |
| Q4 2020 | $56,771,000 | +30.1% | 178,777 | +1.5% | 0.01% | +20.0% |
| Q3 2020 | $43,639,000 | +29.6% | 176,156 | +38.1% | 0.01% | +25.0% |
| Q2 2020 | $33,674,000 | +795.6% | 127,519 | +543.1% | 0.00% | +300.0% |
| Q1 2020 | $3,760,000 | -17.1% | 19,830 | -4.0% | 0.00% | 0.0% |
| Q4 2019 | $4,535,000 | +13.4% | 20,661 | +1.1% | 0.00% | 0.0% |
| Q3 2019 | $3,998,000 | -4.9% | 20,434 | +1.4% | 0.00% | 0.0% |
| Q2 2019 | $4,203,000 | +8.1% | 20,161 | +3.0% | 0.00% | 0.0% |
| Q1 2019 | $3,888,000 | +46.1% | 19,582 | +6.5% | 0.00% | – |
| Q4 2018 | $2,661,000 | -9.7% | 18,390 | +27.4% | 0.00% | – |
| Q3 2018 | $2,946,000 | +38.1% | 14,431 | +0.0% | 0.00% | – |
| Q2 2018 | $2,134,000 | -1.8% | 14,424 | +0.2% | 0.00% | – |
| Q1 2018 | $2,174,000 | +17.1% | 14,395 | +0.5% | 0.00% | – |
| Q4 2017 | $1,856,000 | -6.6% | 14,330 | -12.9% | 0.00% | – |
| Q3 2017 | $1,988,000 | +3.0% | 16,446 | +0.1% | 0.00% | – |
| Q2 2017 | $1,930,000 | +24.4% | 16,426 | +7.6% | 0.00% | – |
| Q1 2017 | $1,551,000 | +8.5% | 15,262 | +9.7% | 0.00% | – |
| Q4 2016 | $1,430,000 | -6.1% | 13,909 | +0.0% | 0.00% | – |
| Q3 2016 | $1,523,000 | -21.5% | 13,907 | -19.2% | 0.00% | – |
| Q2 2016 | $1,940,000 | +12.9% | 17,207 | -5.4% | 0.00% | – |
| Q1 2016 | $1,718,000 | +23.2% | 18,181 | +17.4% | 0.00% | – |
| Q4 2015 | $1,394,000 | -35.1% | 15,491 | -33.3% | 0.00% | – |
| Q3 2015 | $2,147,000 | -6.0% | 23,223 | +0.1% | 0.00% | – |
| Q2 2015 | $2,284,000 | +19.1% | 23,193 | +21.3% | 0.00% | – |
| Q1 2015 | $1,918,000 | +14.6% | 19,123 | +5.6% | 0.00% | – |
| Q4 2014 | $1,674,000 | – | 18,113 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |